Evaluation of Erythropoietin on Alveolar Ridge Preservation
Evaluation of Erythropoietin on Alveolar Ridge Preservation: (A Randomized Controlled Clinical Trial With Histomorphometric Assessment)
Ain Shams University
15 participants
Jan 1, 2024
INTERVENTIONAL
Conditions
Summary
regenerative materials would help in decreasing post-extraction resorption in sites indicated for placement of a conventional bridge or prosthetically driven implant. Erythropoietin (EPO) is a growth factor that promotes angiogenesis and bone regeneration by stimulating osteoblastic differentiation and by inhibiting osteoclastic resorption. Post-extraction alveolar ridge resorption creates morphological and volumetric changes. These changes can be considered of clinical value that may threaten the placement of a conventional bridge or an implant-supported crown. Atwood et al. \[1\] in a cephalometric study categorized factors influencing the rate of alveolar ridge resorption into 4 types: anatomic, metabolic, functional, and prosthetic. As stated by Tan et al. \[2\] in a systematic review of alveolar hard and soft tissue dimensional changes in humans post-extraction, they found that alveolar ridge resorption occurs to a greater extent in a horizontal direction than vertical. Therefore, alveolar ridge preservation (ARP) procedures were introduced in an attempt to prevent hard and soft tissue dimensional changes following extraction.
Eligibility
Inclusion Criteria6
- Age range (18-40).
- Hopeless teeth indicated for extraction such as root fractures, caries, internal root resorption, external root resorption, endodontic failures.
- Systemically free patients using Cornell Medical Index-Health Questionnaire \[36\].
- Patients diagnosed with intact surrounding alveolar bone (socket type I) \[37\].
- Maxillary anterior teeth and/or premolars indicated for extraction.
- Enough zone of keratinized tissue (≥2 mm).
Exclusion Criteria4
- Smokers
- Occlusal trauma at the site of the graft
- Pregnancy and lactation
- Bad compliance with the plaque control instructions following initial therapy.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patient will have extraction of teeth and placement of Erythropoietin carried on chitosan carrier for six months to enhance bone healing
inert scaffold agent
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06513039